几十年来,细胞毒性化疗一直是治疗 B-ALL 的主要手段,但由于老年(≥60岁)ALL患者疾病具有高危生物学特性,且难以耐受标准化疗,预后通常较差,5年总生存率约为20%。尽管随着临床研究的不断探索,B-ALL的治疗已经取得了长足的进步,但在B-ALL老...
5.Elias Jabbour, et al. BLINATUMOMAB ALTERNATING WITH LOW-INTENSITYCHEMOTHERAPY (LIC) IN OLDER ADULTS WITH NEWLY DIAGNOSED B-CELLACUTE LYMPHOBLASTIC LEUKEMIA (ALL): SAFETY RUN-IN FOLLOW-UP FORTHE PHASE 3 GOLDEN GATE. 20...
Tong Wang, Ming Liu, Panxiang Cao, Jiancheng Fang, Huanhuan Li, Jiaqi Chen, Hongxing Liu. Decipher structural aberrations of the PAX5 gene and their correlation with diagnostic classification and treatment outcome in B cell lymphoblastic leukemia. EHA 2023 Abstract P346 专家简介 王彤 教授 临床医学...
Learn about BLINCYTO®, a treatment for B-cell precursor acute lymphoblastic leukemia (ALL). See Safety Info, including Boxed Warnings.
B-cell acute lymphoblastic leukemia (B-ALL) and Burkitt's lymphoma are generally discussed together because the distinction between the two is somewhat arbitrary. Children with an abdominal Burkitt's tumor and >25% marrow blasts are considered to have B-ALL, whereas those with <25% blasts are...
编者按:2019年5月20日,著名血液学期刊Leukemia杂志在线发表了北京博仁医院童春容、潘静医生团队有关CD22 CAR-T细胞疗法治疗复发/难治B细胞急性淋巴细胞白血病(B-ALL)的临床研究。目前,CD22 CAR-T细胞疗法临床研究较少,对于CD19 CAR-T治疗后复发的患者,尝试CD22 CAR-T治疗可为后续移植争取宝贵的时机。据悉,童春容、...
①效应性B细胞(effector B cell,Beff)可产生自身抗体,如类风湿因子(rheumatoid factor,RF)和抗瓜氨酸蛋白抗体(anti-citrulline protein antibody,ACPA)等,这些抗体形成免疫复合物,沉积在关节中,并通过补体和细胞激活促进炎症过程;②B细胞作为有效的抗原提呈细胞(antigen presenting cell,APC),通过共刺激分子的表达激活...
Dr. Lamanna discusses how to sequence Bruton tyrosine kinase (BTK) inhibitors, B-cell lymphoma 2 (BCL2) inhibitors like venetoclax (Venclexta), and newer agents for chronic lymphocytic leukemia (CLL) treatment based on patient factors. In the frontline setting, choice between BTK inhibitor or ...
英文名称:Human B-cell leukemia/lymphoma 2,Bcl-2 elisa Kit 用途:仅供科研使用 纯度:99.99% 产地:国内 品牌:KEMOBio 包装规格:96T/48T 标记物:HRP标记物 样本:血清、血浆、尿液、细胞培养上清、组织匀浆等 检测方法:ELISA(检测法) 应用:科研使用
4. Bologna1 S, Borght TV, Briere J, et al. EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE‐ ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B‐CELL LYMPHOMA (AAIPI=0): RESULTS OF THE PHASE 3 LYSA LNH 09‐ 1B TRIAL. 2021 ICML Abstract S005. ...